期刊文献+

双介入法治疗原发性肝癌疗效的临床研究 被引量:1

Clinical Study on Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Treating Hepatocellular Carcinoma
暂未订购
导出
摘要 目的评价双介入方法治疗原发性肝癌的临床应用价值。方法选择2004年3月至2006年3月期间在我院进行介入治疗的原发性肝癌患者137例,其中行单纯性肝动脉化疗栓塞87例(TACE组),行肝动脉化疗栓塞和经皮肝穿多弹头射频消融双介入治疗50例(双介入组)。全部病例定期做CT复查和AFP测定,观察肿瘤的客观疗效。结果TACE组肿瘤客观有效率(CR+PR)为34.5%,AFP下降幅度54.2%,2年生存率为43.7%;双介入组客观有效率为70.0%,AFP下降幅度78.0%,2年生存率为62.0%,2组间差异均有统计学意义(P<0.05)。结论双介入方法治疗原发性肝癌疗效肯定,优于单纯应用TACE治疗。 Objective To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treating primary hepatocellular carcinoma (HCC). Methods From March 2004 to March 2006, 137 patients with primary HCC underwent TACE alone (n=87) and TACE+RFA (n=50), respectively, after the interventional treatment, all patients periodically received CT reexaminations and alpha fetoprotein (AFP) measurement. The therapeutic efficacy, AFP level and survival rate between two groups were compared with each other. Results In TACE group the effective rate (CR+PR) was 34.5%, AFP decreasing amplitude was 54.2% , and 2 years survival rate was 43.7%. While in TACE+RFA group, the effective rate (CR+PR) was 70.0%, AFP decreasing amplitude was 78.0%, and 2 years survival rate was 62.0%, there were significant differences between two groups (P〈0.05). Conclusion Combined application of TACE and RFA is significantly superior to TACE alone in treatment of primary HCC.
出处 《中国普外基础与临床杂志》 CAS 2008年第9期686-689,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 原发性肝癌 栓塞治疗 多弹头射频 Primary hepatocellular carcinoma Embolization treatment Radiofrequency ablation
  • 相关文献

参考文献10

二级参考文献42

  • 1万向荣,张炳海,郭文源,冯晓灵,李柏,徐卫东,耿兰溪.肝动脉与门静脉双重化疗治疗晚期肝癌(附4例报告)[J].中国肿瘤临床,1993,20(7):557-557. 被引量:9
  • 2孙燕.临床肿瘤内科手册(第2版)[M].北京:人民卫生出版社,1991.23-23.
  • 3单撙.数学奥林匹克,第1版[M].北京:北京大学出版社,1992.495-508,547-562.
  • 4Miao Y, Ni Y,Mulier S,et al. A Comparatibe study on validation of a novel"cooled-wet" electrode for radiofrequency liver ablation. Invest Radiol , 2000 ,35: 438-444.
  • 5Miao Y, Ni Y,Yu J,et al. An in vivo study on radiofrequency tissue ablation: increased lesion size by using an expandable-wet electrode[J]. Euf Radiol,2001,11 : 1841-1847.
  • 6Scott D J,Watumull L M,Young W M. Development of an in vivo tumor-mimic model for learning radiofrequency ablation[J], J Gastrointest Surg. 2000 Nov-Dec;4(6) : 620-625.
  • 7Rose Sc,Hassanein Tl,Easter DW,et al. Value of three--dimentional utlrasound for optimizing guidance for ablating focal liver tumors [J ]. J Vasc Interc Radiol, 2001,1294 : 507-515.
  • 8Wallace JR, Christian KK,Quiroz DW,et al. Ablation of liver metastasis: is preoperative imaging sufficiently accurate? J Gastrointest Surg. 2001,5(1) ;98-107.
  • 9Solbiati L,Goldberg SN,Ierace T, et al. Radiofrequency ablation of hepatic metastases:postproceduaral assessment with a US microbubble contrast agent-early experience[J]. Radiology,1999,211 : 634-649.
  • 10Yamasaki T, Kurokawa F,Shirahashi H et al. Percutaneous radiofrequency ablation theerapy with combined angiography and computed tornography assistance for patients with hepatocellular carcinoma. Cancer. 2001,91 (7) : 1342-1348.

共引文献250

同被引文献26

  • 1吴育连,苏昆仑,董鑫,于俊秀,彭淑牖.肝癌切除术后早/晚期复发的危险因素与治疗[J].中华肝胆外科杂志,2006,12(6):370-373. 被引量:23
  • 2张坤,江艺,张绍庚,谢海英,谢志红.肝动脉化疗栓塞对原发性肝癌患者术后生存及肿瘤复发的影响[J].中国普通外科杂志,2007,16(3):206-208. 被引量:16
  • 3Poon RT, Fan ST, Ng IO, et al. Different risk factors and prog- nosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma [J]. Cancer, 2000, 89(3): 500-507.
  • 4Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implica- tions of extended-speclnma beta-lactamase production in nosocomial infections [J]. Ann Intern Med, 2004, 140(1): 26-32.
  • 5Bruix J, Hessheimer AJ, Fomer A, et al. New aspects of diag- nosis and therapy of hepatocellular carcinoma [J]. Oncogene, 2006, 25(27): 3848-3856.
  • 6Zhong JH, Li le Q, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma [ J ]. Cochrane Database Syst Rev, 2011, (12): CD008713.
  • 7Lu X, Zhao H, Yang H, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatec- tomy [J]. J Surg Oncol, 2009, 100(6): 488-493.
  • 8Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma [J]. Hepatology, 1994, 20(2): 295-301.
  • 9Kwok PC, Lam TW, Lam PW, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma [ J ]. J Crastroenterol Hepatol, 2003, 18(4): 450-455.
  • 10Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [J]. Hepatology, 2003, 37(2): 429-442.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部